Showing results (11-20 of 96) with videos related to

Sort By:
Pageof 10
Biotechnology and Bioengineering|February 4, 2019
Electron-acceptor loadings affect chloroform dechlorination in a hydrogen-based membrane biofilm reactorYenJung Sean Lai, Aura Ontiveros-Valencia, Tamer Coskun, et al.
Brain Research|July 20, 2010
Pattern of Fos expression in the brain induced by selective activation of somatostatin receptor 2 in ratsMiriam Goebel, Andreas Stengel, Lixin Wang, et al.
The Lancet. Diabetes & Endocrinology|July 3, 2025
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trialTamer Coskun, Qiwei Wu, Nanette C Schloot, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|June 26, 2015
Viral transduction of renin rapidly establishes persistent hypertension in diverse murine strainsShannon M Harlan, Robert A Ostroski, Tamer Coskun, et al.
Endocrinology|July 9, 2010
Central injection of the stable somatostatin analog ODT8-SST induces a somatostatin2 receptor-mediated orexigenic effect: role of neuropeptide Y and opioid signaling pathways in ratsAndreas Stengel, Tamer Coskun, Miriam Goebel, et al.
Diabetes, Obesity & Metabolism|June 2, 2023
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetesEdward Pratt, Xiaosu Ma, Rong Liu, et al.
Molecular Metabolism|September 12, 2013
The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissueAndrew C Adams, Chaofeng Yang, Tamer Coskun, et al.
Molecular Metabolism|September 20, 2013
Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinedionesAndrew C Adams, Tamer Coskun, Christine C Cheng, et al.
Diabetes, Obesity & Metabolism|June 22, 2023
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participantsEdward Pratt, Xiaosu Ma, Rong Liu, et al.
Kidney International Reports|July 9, 2025
The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or ObesityHiddo J L Heerspink, Zeqing Lu, Yu Du, et al.
Pageof 10